Skip to main content

Table 4 Response

From: Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data

 

SP (n = 157)

Non-SP (n = 155)

p-value

Best response

   

 CR

2

4

 

 PR

107

106

 

 SD

36

36

 

 PD

8

7

 

 NE

4

2

 

ORR

   

 CR + PR

109 (69.4%)

110 (70.9%)

0.431

  (95% CI)

(62.1–76.7)

(63.7–78.1)

 

DCR

   

 CR + PR + SD

145 (92.3%)

146 (94.1%)

0.337

  (95% CI)

(88.1–96.5)

(90.4–97.9)

 
  1. SP, S-1 + cisplatin; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable; ORR, overall response rate; DCR, disease control rate
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us